CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (USD $) In Millions, except Share data, unless otherwise specified	Total	Common Shares	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Valeant Pharmaceuticals International, Inc. Shareholders' equity	Noncontrolling Interest	Comprehensive Loss
Balance at Dec. 31, 2011	$ 3,929.8	$ 5,963.6	$ 276.1	$ (2,030.3)	$ (279.6)	$ 3,929.8	$ 0
Balance (in shares) at Dec. 31, 2011		306,400,000
Increase (Decrease) in Shareholders' Equity
Settlement of 5.375% Convertible Notes	(43.8)		(0.2)	(43.6)		(43.8)
Repurchase of equity component of 5.375% Convertible Notes	(2.9)		(0.2)	(2.7)		(2.9)
Common shares issued under share-based compensation plans (in shares)		2,800,000
Common shares issued under share-based compensation plans	23.2	79.4	(56.2)			23.2
Repurchase of common shares (in shares)		(5,300,000)
Repurchase of common shares	(280.7)	(102.3)		(178.4)		(280.7)
Share-based compensation	66.2		66.2			66.2
Employee withholding taxes related to share-based awards	(31.1)		(31.1)			(31.1)
Tax benefits from stock options exercised	12.5		12.5			12.5
Total before comprehensive income (loss) (in shares)		303,900,000
Total before comprehensive income (loss)	3,673.2	5,940.7	267.1	(2,255.0)	(279.6)	3,673.2	0
Net income (loss) attributable to Valeant Pharmaceuticals International, Inc.	(116.0)
Comprehensive income:
Net income (loss)	(116.0)			(116.0)		(116.0)		(116.0)
Less: Net (loss) income attributable to noncontrolling interest	0
Other comprehensive income (loss)					160.2	160.2		160.2
Comprehensive income (loss)	44.2					44.2		44.2
Balance at Dec. 31, 2012	3,717.4	5,940.7	267.1	(2,371.0)	(119.4)	3,717.4	0
Balance (in shares) at Dec. 31, 2012		303,900,000
Increase (Decrease) in Shareholders' Equity
Issuance of common stock (in shares)		27,600,000
Issuance of common stock	2,306.9	2,306.9				2,306.9
Common shares issued under share-based compensation plans (in shares)		2,200,000
Common shares issued under share-based compensation plans	6.4	67.8	(61.4)			6.4
Repurchase of common shares (in shares)		(700,000)
Repurchase of common shares	(55.6)	(14.2)		(41.4)		(55.6)
Share-based compensation	45.5		45.5			45.5
Employee withholding taxes related to share-based awards	(46.6)		(46.6)			(46.6)
Tax benefits from stock options exercised	24.2		24.2			24.2
Noncontrolling interest from business combinations	113.9						113.9
Noncontrolling interest distributions	(2.1)						(2.1)
Total before comprehensive income (loss) (in shares)		333,000,000
Total before comprehensive income (loss)	6,110.0	8,301.2	228.8	(2,412.4)	(119.4)	5,998.2	111.8
Net income (loss) attributable to Valeant Pharmaceuticals International, Inc.	(866.1)
Comprehensive income:
Net income (loss)	(863.6)			(866.1)		(866.1)	2.5	(863.6)
Less: Net (loss) income attributable to noncontrolling interest	2.5
Other comprehensive income (loss)					(13.4)	(13.4)	0.3	(13.1)
Comprehensive income (loss)	(876.7)					(879.5)	2.8	(876.7)
Balance (including portion attributable to non-controlling interest) at Dec. 31, 2013	5,233.3	8,301.2	228.8	(3,278.5)	(132.8)	5,118.7	114.6
Balance at Dec. 31, 2013	5,118.7
Balance (in shares) at Dec. 31, 2013	333,036,637	333,000,000
Increase (Decrease) in Shareholders' Equity
Common shares issued under share-based compensation plans (in shares)		1,400,000
Common shares issued under share-based compensation plans	16.1	48.0	(31.9)			16.1
Settlement of stock options	(3.1)		(3.1)			(3.1)
Share-based compensation	78.2		78.2			78.2
Employee withholding taxes related to share-based awards	(44.1)		(44.1)			(44.1)
Tax benefits from stock options exercised	17.1		17.1			17.1
Noncontrolling interest from business combinations	15.0						15.0
Acquisition of noncontrolling interest	(3.3)		(1.1)			(1.1)	(2.2)
Noncontrolling interest distributions	(2.2)						(2.2)
Total before comprehensive income (loss) (in shares)		334,400,000
Total before comprehensive income (loss)	5,307.0	8,349.2	243.9	(3,278.5)	(132.8)	5,181.8	125.2
Net income (loss) attributable to Valeant Pharmaceuticals International, Inc.	913.5			913.5
Comprehensive income:
Net income (loss)	912.2					913.5	(1.3)	912.2
Less: Net (loss) income attributable to noncontrolling interest	(1.3)
Other comprehensive income (loss)					(783.1)	(783.1)	(1.6)	(784.7)
Comprehensive income (loss)	127.5					130.4	(2.9)	127.5
Balance (including portion attributable to non-controlling interest) at Dec. 31, 2014	5,434.5	8,349.2	243.9	(2,365.0)	(915.9)	5,312.2	122.3
Balance at Dec. 31, 2014	$ 5,312.2
Balance (in shares) at Dec. 31, 2014	334,402,964	334,400,000